Associations among hearing loss, multiple co-occurring symptoms, and quality of life outcomes in cancer survivors
- PMID: 36454519
- PMCID: PMC9714406
- DOI: 10.1007/s11764-022-01301-0
Associations among hearing loss, multiple co-occurring symptoms, and quality of life outcomes in cancer survivors
Abstract
Purpose: Evaluate for differences in demographic and clinical characteristics, occurrence of common symptoms, symptom severity scores, and quality of life (QOL) outcomes in survivors with (n = 155) and without (n = 118) audiometrically confirmed hearing loss.
Methods: Survivors, who were recruited from throughout the San Francisco Bay area, completed the self-report questionnaires to obtain the information of demographic and clinical characteristics; the occurrence and severity of depression, anxiety, fatigue, decrements in energy, sleep disturbance, pain, and cognitive impairment; and the general and cancer-specific QOL outcomes. Parametric and non-parametric tests were used to evaluate for differences between the two survivor groups.
Results: Survivors with audiometrically confirmed hearing loss were older, more likely to be male, were more likely to be unemployed, report a lower annual household income, and had a higher comorbidity burden. Except for the severity of worst pain, no between-group differences were found in the occurrence rates for or severity of any of the symptoms. Survivors with hearing loss reported worse physical function and general health scores.
Conclusions: While no between-group differences in symptom occurrence rates and severity scores were found, across the total sample, a relatively high percentage of survivors who were over 6 years from their cancer diagnosis reported clinically meaningful levels of depression (25%), anxiety (50%), fatigue (40%), decrements in energy (70%), sleep disturbance (58%), cognitive impairment (57%), and pain (60%).
Implications for cancer survivors: Clinicians need to perform routine assessments of hearing loss, as well as common co-occurring symptoms and initiate individualized symptom management interventions.
Keywords: Cancer; Chemotherapy; Depression; Fatigue; Hearing loss; Patient-reported outcomes; Quality of life; Sleep disturbance; Symptoms.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy.Eur J Oncol Nurs. 2018 Feb;32:1-11. doi: 10.1016/j.ejon.2017.10.006. Epub 2017 Nov 7. Eur J Oncol Nurs. 2018. PMID: 29353626 Free PMC article.
-
Patients with palpitations experience a higher symptom burden prior to breast cancer surgery.Eur J Oncol Nurs. 2023 Aug;65:102341. doi: 10.1016/j.ejon.2023.102341. Epub 2023 May 1. Eur J Oncol Nurs. 2023. PMID: 37327556
-
Comparison of fatigue and fatigability correlates in Korean breast cancer survivors and differences in associations with anxiety, depression, sleep disturbance, and endocrine symptoms: a randomized controlled trial.BMC Cancer. 2021 Jul 26;21(1):855. doi: 10.1186/s12885-021-08575-0. BMC Cancer. 2021. PMID: 34311713 Free PMC article.
-
Distinct Wound Healing and Quality-of-Life Outcomes in Subgroups of Patients With Venous Leg Ulcers With Different Symptom Cluster Experiences.J Pain Symptom Manage. 2017 May;53(5):871-879. doi: 10.1016/j.jpainsymman.2016.12.336. Epub 2017 Jan 4. J Pain Symptom Manage. 2017. PMID: 28063868 Review.
-
Interventions for Managing a Symptom Cluster of Pain, Fatigue, and Sleep Disturbances During Cancer Survivorship: A Systematic Review.Oncol Nurs Forum. 2020 Jul 1;47(4):E107-E119. doi: 10.1188/20.ONF.E107-E119. Oncol Nurs Forum. 2020. PMID: 32555558
Cited by
-
Predictors of persistence of post-chemotherapy symptoms among survivors of solid tumor cancers.Qual Life Res. 2024 Apr;33(4):1143-1155. doi: 10.1007/s11136-023-03595-8. Epub 2024 Jan 30. Qual Life Res. 2024. PMID: 38291312 Free PMC article.
-
A Sequential Multiple Assignment Randomized Trial of Symptom Management After Chemotherapy.J Pain Symptom Manage. 2023 Jun;65(6):541-552.e2. doi: 10.1016/j.jpainsymman.2023.02.005. Epub 2023 Feb 17. J Pain Symptom Manage. 2023. PMID: 36801353 Free PMC article. Clinical Trial.
-
Survivors' perspectives on cisplatin-induced ototoxicity and barriers to ototoxicity monitoring.J Cancer Surviv. 2025 Jul 2. doi: 10.1007/s11764-025-01860-y. Online ahead of print. J Cancer Surviv. 2025. PMID: 40601160